Back to Results

Impact Biomedical Inc (IBO)

Featured in Overvalued Stocks

Impact Biomedical Inc. is a Houston-based healthcare company focused on discovering, developing, and commercializing products and technologies aimed at unmet needs in human health and wellness. The company’s work spans specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. Its pipeline includes Linebacker, a small-molecule platform based on electrophilically enhanced polyphenol compounds with applications in oncology, inflammatory disorders, and neurology; Laetose, a sugar-and-inositol technology designed to affect inflammatory and metabolic responses; and Equivir/Equivir G, a polyphenol-based blend being developed for potential antiviral use in supplements and medications. Impact Biomedical is also developing functional fragrance formulations with botanical ingredients for antimicrobial and other consumer applications. The company was incorporated in 2018 and operates as a subsidiary of DSS BioHealth Security, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-IBO
$0.26
-41.9% Downside
Overvalued
—
—
—
Weak
—
—
—
0.0%
August 13, 2026
-3.8x
4.2x
1,244.1x
47.98 M
52.85 M
2.1%
10.7%
-232.7
—
13.0%
Send a message
Valuation • Fair Value

Impact Biomedical Inc (NYSE-IBO) Fair Value by Valuation Model

Compare the primary fair value estimate for Impact Biomedical Inc (NYSE-IBO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.26

Estimated downside of 41.9% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.26

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Impact Biomedical Inc (NYSE-IBO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Impact Biomedical Inc (NYSE-IBO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

39 K

Current operating scale indicator.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-4.12 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Impact Biomedical Inc (NYSE-IBO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Impact Biomedical Inc (NYSE-IBO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-232.7

Lower score that deserves closer risk review.

FCF / Net Income

13.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Impact Biomedical Inc (NYSE-IBO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Impact Biomedical Inc (NYSE-IBO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Impact Biomedical Inc (NYSE-IBO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Impact Biomedical Inc (NYSE-IBO) Stock Forecast & Technical Outlook

Review Impact Biomedical Inc (NYSE-IBO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Impact Biomedical Inc (NYSE-IBO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Impact Biomedical Inc (NYSE-IBO) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Impact Biomedical Inc (NYSE-IBO) Stock FAQ

Quick answers about Impact Biomedical Inc (NYSE-IBO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.26
Estimated downside 41.9%
Valuation Rating
Overvalued
Estimated downside of 41.9%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Impact Biomedical Inc (NYSE-IBO) is $0.26. This implies an estimated downside of 41.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 41.9% versus the current market price.

An analyst price target for Impact Biomedical Inc (NYSE-IBO) is not currently available in the latest data file.

The current financial health read for Impact Biomedical Inc (NYSE-IBO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Impact Biomedical Inc (NYSE-IBO) is August 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Impact Biomedical Inc (NYSE-IBO) is -3.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Impact Biomedical Inc is 47.98 M.

The current enterprise value listed for Impact Biomedical Inc is 52.85 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Impact Biomedical Inc is NYSE-IBO, and the stock is listed on NYSE.

Impact Biomedical Inc (NYSE-IBO) is listed on NYSE.

The current debt-to-total-capital ratio listed for Impact Biomedical Inc is 2.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Impact Biomedical Inc is 10.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NYSE View more

Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Johnson & Johnson (JNJ) Johnson & Johnson (JNJ)
Merck & Company Inc (MRK) Merck & Company Inc (MRK)
Novartis AG ADR (NVS) Novartis AG ADR (NVS)
Novo Nordisk A/S (NVO) Novo Nordisk A/S (NVO)
Pfizer Inc (PFE) Pfizer Inc (PFE)
Bristol-Myers Squibb Company (BMY) Bristol-Myers Squibb Company (BMY)
GSK plc DRC (GSK) GSK plc DRC (GSK)
Takeda Pharmaceutical Co Ltd ADR (TAK) Takeda Pharmaceutical Co Ltd ADR (TAK)
HALEON PLC ADR (HLN) HALEON PLC ADR (HLN)
Teva Pharma Industries Ltd ADR (TEVA) Teva Pharma Industries Ltd ADR (TEVA)
Zoetis Inc (ZTS) Zoetis Inc (ZTS)
Elanco Animal Health (ELAN) Elanco Animal Health (ELAN)
Dr. Reddy’s Laboratories Ltd ADR (RDY) Dr. Reddy’s Laboratories Ltd ADR (RDY)
Veradermics Inc (MANE) Veradermics Inc (MANE)
Organon & Co (OGN) Organon & Co (OGN)
Prestige Consumer Healthcare Inc (PBH) Prestige Consumer Healthcare Inc (PBH)
Nuvation Bio Inc (NUVB) Nuvation Bio Inc (NUVB)
Bausch Health Companies Inc (BHC) Bausch Health Companies Inc (BHC)
Perrigo Company PLC (PRGO) Perrigo Company PLC (PRGO)
Alto Neuroscience Inc (ANRO) Alto Neuroscience Inc (ANRO)
Rafael Holdings Inc Class B (RFL) Rafael Holdings Inc Class B (RFL)
China Pharma Holdings Inc (CPHI) China Pharma Holdings Inc (CPHI)
Nasus Pharma Ltd (NSRX) Nasus Pharma Ltd (NSRX)